Results 71 to 80 of about 14,145 (218)

Meningococcal vaccine and herd immunity [PDF]

, 2000
Achille Gikas, John Pediaditis, Yannis Tselentis   +2 more
openalex   +3 more sources

Summary of the NACI Statement on the Use of Bivalent Factor H Binding Protein Meningococcal Serogroup B (MenB-fHBP) Vaccine for the Prevention of Meningococcal B Disease

Canada Communicable Disease Report, 2020
Background: Trumenba™, a bivalent, factor-H binding protein meningococcal serogroup B (MenB-fHBP) vaccine was authorized for use in Canada in October 2017 for the prevention of invasive meningococcal disease (IMD) caused by Neisseria meningitidis ...
Robyn Harrison, Robert Stirling, Oliver Baclic, Wendy Vaudry   +3 more
doaj   +1 more source

Meningococcal vaccines.

Current opinion in investigational drugs (London, England : 2000), 2003
Neisseria meningitidis is one of the leading infectious causes of death in children under five years old in industrialized countries, and most cases can be attributed to five disease-causing serogroups: A, B, C, Y and W135. Meningococcal vaccine development began in the 1930s with killed whole-cell and exotoxin vaccines, but widespread use of ...
Collins, C, Pollard, A
openaire   +2 more sources

Prevention of Meningococcal Disease: Knowledge, Attitudes, and Practices of General Practitioners and Primary Care Pediatricians in South Italy

Vaccines
Background: The purpose of this study was to evaluate the knowledge, attitude, and current practices about prevention of meningococcal disease among general practitioners (GPs) and primary care pediatricians (PCPs) in Italy.
Silvia Angelillo, Concetta Paola Pelullo, Francesca Licata, Raffaele Lanzano, Francesco Napolitano, Gabriella Di Giuseppe   +5 more
doaj   +1 more source

Preparation and immunochemical characterization of meningococcal group C polysaccharide-tetanus toxoid conjugates as a new generation of vaccines [PDF]

, 1983
E. C. Beuvery, Frank Miedema, R. van Delft, J. Haverkamp   +3 more
openalex   +1 more source

Construction of a multivalent meningococcal vaccine strain based on the class 1 outer membrane protein [PDF]

, 1992
Peter van der Ley, Jan Poolman
openalex   +1 more source

Meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine: a new conjugate vaccine against invasive meningococcal disease

Infection and Drug Resistance, 2014
Carine P Hedari,* Rima W Khinkarly,* Ghassan S Dbaibo Center for Infectious Diseases Research, Division of Pediatric Infectious Diseases, Department of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center, Beirut, Lebanon ...
Hedari CP, Khinkarly RW, Dbaibo GS
doaj  

Efficacy and Safety of Quadrivalent Conjugate Meningococcal Vaccines: A Systematic Review and Meta-Analysis. [PDF]

Vaccines (Basel), 2023
Conti A, Broglia G, Sacchi C, Risi F, Barone-Adesi F, Panella M.   +5 more
europepmc   +1 more source

Current status of meningococcal group B vaccine candidates: capsular or noncapsular? [PDF]

, 1994
José Diaz‐Romero, I Outschoorn
openalex   +1 more source

Advances in meningococcal vaccines

Clinical Practice, 2012
SUMMARY During the 20th century, meningococcal vaccine manufacturers took advantage of conjugate technology to provide products that could protect infants, the most vulnerable population, against invasive disease caused by serogroup C. These conjugate vaccines induce anamnestic responses and induce herd protection.
Lisa DeTora, James Wassil, Mariagrazia Pizza   +2 more
openaire   +2 more sources